» Articles » PMID: 32974855

Nesfatin-1 Promotes Proliferation, Migration and Invasion of HTR-8/SVneo Trophoblast Cells and Inhibits Oxidative Stress Via Activation of PI3K/AKT/mTOR and AKT/GSK3β Pathway

Overview
Journal Reprod Sci
Publisher Springer
Date 2020 Sep 25
PMID 32974855
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Preeclampsia (PE) is a leading cause of perinatal and maternal mortality. Considering that Nesfatin-1 was reported to be downregulated in serum of PE patients, we aimed to explore the functional role of Nesfatin-1 in trophoblast cells. Cell transfection was conducted to overexpress or inhibit Nesfatin-1, and its expression was measured by quantitative PCR. Cell proliferation, migration, and invasion abilities were determined employing CCK-8, flow cytometry, wound-healing, and transwell assays. Immunofluorescence assay was performed to detect E-cadherin and vimentin. ROS, MDA, and SOD levels were measured using their corresponding commercial kits. Western blot was used to identify the expression of vital kinases in PI3K/AKT/mTOR or GSK3β pathway and invasion-related proteins in trophoblast cells. Nesfatin-1 knockdown significantly suppressed proliferation, migration, and invasion and increased cell arrest in G1 phase, as well as downregulated expressions of MMP2/9 in HTR-8/SVneo cells. Besides, Nesfatin-1 knockdown promoted the expression of E-cadherin and reduced the expression of vimentin. Additionally, the levels of ROS, MDA, and SOD were elevated upon Nesfatin-1 knockdown. On the contrary, Nesfatin-1 overexpression exerted the opposite effects. Nesfatin-1 promoted the activation of PI3K/AKT/mTOR or GSK3β pathway, blocking of which reversed the promotive effects on trophoblast invasion and the inhibitory effects on oxidative stress of Nesfatin-1 in HTR-8/SVneo cells. In short, this study revealed that Nesfatin-1 promoted trophoblast cell proliferation, migration, invasion, and EMT and suppressed oxidative stress by activating PI3K/AKT/mTOR and AKT/GSK3β signaling pathway, laying the foundation for the development of therapeutic strategy for PE by targeting Nesfatin-1.

Citing Articles

Nutraceuticals as Modulators of Molecular Placental Pathways: Their Potential to Prevent and Support the Treatment of Preeclampsia.

Bukowska P, Bralewska M, Pietrucha T, Sakowicz A Int J Mol Sci. 2024; 25(22).

PMID: 39596234 PMC: 11594370. DOI: 10.3390/ijms252212167.


The Role of Catestatin in Preeclampsia.

Bralewska M, Pietrucha T, Sakowicz A Int J Mol Sci. 2024; 25(5).

PMID: 38473713 PMC: 10931722. DOI: 10.3390/ijms25052461.


Nuclear Binding Protein 2/Nesfatin-1 Affects Trophoblast Cell Fusion during Placental Development via the EGFR-PLCG1-CAMK4 Pathway.

Dang Q, Zhu Y, Zhang Y, Hu Z, Wei Y, Chen Z Int J Mol Sci. 2024; 25(3).

PMID: 38339201 PMC: 10856506. DOI: 10.3390/ijms25031925.


Unraveling the molecular mechanisms driving enhanced invasion capability of extravillous trophoblast cells: a comprehensive review.

Lin Z, Wu S, Jiang Y, Chen Z, Huang X, Wen Z J Assist Reprod Genet. 2024; 41(3):591-608.

PMID: 38315418 PMC: 10957806. DOI: 10.1007/s10815-024-03036-6.


Death receptor 3 is involved in preeclampsia through regulating placental trophoblast cell physiology by inactivating the PI3K/AKT pathway.

Yin C, Wang J, Zhang Y, Zhang X, Zhao W, Shen Y Immun Inflamm Dis. 2023; 11(9):e995.

PMID: 37773709 PMC: 10523955. DOI: 10.1002/iid3.995.


References
1.
Leslie M, Briggs L . Preeclampsia and the Risk of Future Vascular Disease and Mortality: A Review. J Midwifery Womens Health. 2016; 61(3):315-24. DOI: 10.1111/jmwh.12469. View

2.
Xiao J, Shen F, Xue Q, Chen G, Zeng K, Stone P . Is ethnicity a risk factor for developing preeclampsia? An analysis of the prevalence of preeclampsia in China. J Hum Hypertens. 2014; 28(11):694-8. DOI: 10.1038/jhh.2013.148. View

3.
Roberts J, Gammill H . Preeclampsia: recent insights. Hypertension. 2005; 46(6):1243-9. DOI: 10.1161/01.HYP.0000188408.49896.c5. View

4.
Behrens I, Basit S, Lykke J, Ranthe M, Wohlfahrt J, Bundgaard H . Association Between Hypertensive Disorders of Pregnancy and Later Risk of Cardiomyopathy. JAMA. 2016; 315(10):1026-33. DOI: 10.1001/jama.2016.1869. View

5.
Steegers E, von Dadelszen P, Duvekot J, Pijnenborg R . Pre-eclampsia. Lancet. 2010; 376(9741):631-44. DOI: 10.1016/S0140-6736(10)60279-6. View